Overview
Lobbying Costs
250,000€
Financial year: Jan 2017 - Dec 2017
Lobbyists (Full time equivalent)
1.25 Fte (4)
Lobbyists with EP accreditation
3
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Alexion Pharmaceuticals (Alexion)
EU Transparency Register
611074012464-89 First registered on 18 Dec 2013
Goals / Remit
Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope.
Our first commercial product is Soliris® (eculizumab), the world's first and only approved terminal complement inhibitor. Today, Soliris is approved in nearly 50 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union, Japan and other countries as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases.
In August 2017 the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive, an ultra-rare subset of patients who continues to suffer from severe disease symptoms and complications despite therapies currently used for MG, a debilitating, chronic and progressive autoimmune neuromuscular disease.
Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders: Strensiq® (asfotase alfa) is approved for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) is approved for patients with lysosomal acid lipase deficiency (LAL-D).Main EU files targeted
Alexion monitors and follows policy of relevance for the biopharmaceutical sector. It interacts with the EU institutions and engages in issues relating to healthcare, pharmaceuticals, patient safety, research and innovation, competitiveness and internal market.
Address
Head Office
College Street 100
New Haven CT 06510
UNITED STATESEU Office
Alexion Services Europe
Rue de la Régence 58
Brussels 1000
BELGIUM -
People
Total lobbyists declared
4
Employment time Lobbyists 50% 1 25% 3 Lobbyists (Full time equivalent)
1.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
3 accreditations were / are live (in bold) for the selected state of 08 Mar 2018
Name Start date End Date Matthias Heck 28 Jun 2023 27 Jun 2024 Matthias Heck 14 Feb 2020 01 Mar 2021 Matthias Heck 02 Aug 2018 01 Sep 2019 Claire ALBANO 17 Oct 2017 08 Jun 2018 Mr Thibault, Marie Bruno De Lary de Latour 17 Oct 2017 21 Sep 2018 Matthias Heck 27 Jun 2017 21 Jun 2018 Claire ALBANO 22 Oct 2016 17 Oct 2017 Mr Thibault, Marie Bruno De Lary de Latour 22 Oct 2016 17 Oct 2017 Mr Gregory KALBAUGH 30 Sep 2016 23 Sep 2017 Mr David Newman 22 Aug 2016 30 Jul 2017 Matthias Heck 20 Feb 2016 19 Feb 2017 Ms Heidi Wagner 29 Oct 2015 23 Oct 2016 Claire ALBANO 29 Oct 2015 22 Oct 2016 Mr Thibault, Marie Bruno De Lary de Latour 29 Oct 2015 22 Oct 2016 Ms Grainne Madeline Crowley 29 Oct 2015 23 Oct 2016 Mr Gregory KALBAUGH 04 Sep 2015 02 Sep 2016 Ms Grainne Madeline Crowley 20 Nov 2014 29 Oct 2015 Mr Thibault, Marie Bruno De Lary de Latour 20 Nov 2014 29 Oct 2015 Mrs Grainne Madeline Crowley 20 Nov 2014 27 Jan 2015 Ms Heidi Wagner 19 Nov 2014 29 Oct 2015 Mr André Zöller 19 Nov 2014 29 Jul 2015 Claire ALBANO 19 Nov 2014 29 Oct 2015 Complementary Information
The Government Affairs team has a broad range of national activities that go beyond EU policies. This explains the percentage indicated for EU related activities.
Person in charge of EU relations
Mr Thibault De Lary de Latour (Executive Director Global Value, Access and Policy)
Person with legal responsibility
Mr Thibault De Lary de Latour (Executive Director Global Value, Access and Policy)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Alexion is member of the following organisations in Brussels:
•EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
•EAPM - European Alliance for Personalised Medicine
•EURORDIS Roundtable of Companies (ERTC) - European Organisation for Rare DiseasesMember organisations
Member of:
EUCOPE - http://www.eucope.org/en/
EAPM - https://www.euapm.eu/
EURORDIS - https://www.eurordis.org/ertc/ -
Financial Data
Closed financial year
Jan 2017 - Dec 2017
Lobbying costs for closed financial year
250,000€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
- European Commission consultation on SPC
- European Commission Regulation on health technology assessment and amending Directive 2011/24/EU
- European Commission study on the evaluation of the EU orphan legislationOther activities
Raise awareness in the field of severe and life-threatening rare and ultra-rare diseases for which few or no treatments exist, and which affect very small numbers of patients.
Alexion supports equal access to innovative and life-transforming therapies in the healthcare sector and actively engages in debates on issues relevant to the biopharmaceutical sector.
Meetings
Meetings
None declared